Citations

Clear

2960 citation(s) found for "Kim, P".

Differential Expression of Activating Transcription Factor-2 and c-Jun in the Immature and Adult Rat Hippocampus Following Lithium-Pilocarpine Induced Status Epilepticus
Han, Si‐Ryung, Shin, Cheolsu, Park, Seongkyung, Rhyu, Seonyoung, Park, Jeong‐Wook , Kim, Yeong In, Kim, Yeong-In

Mayo Clinic

Yonsei Medical Journal | May 6, 2009 | Volume: 50 | Issue: 2 | Pages: 200

10.3349/ymj.2009.50.2.200 | PMID 19430551 Get It

Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841
Kim, George P., Sargent, Daniel J. , Mahoney, Michelle R., Rowland, Kendrith M. , Mitchell, Edith P. , Mathews, Abraham P., Fitch, Tom R., Goldberg, Richard M. , Pitot, Henry C., Philip, Philip A. , Alberts, Steven R. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | April 21, 2009 | Volume: 27 | Issue: 17 | Pages: 2848-2854

10.1200/jco.2008.20.4552 | PMID 19380443 Get It

Purpose The primary goal of this multicenter phase III trial was to determine whether overall survival (OS) of fluorouracil (FU) -refractory patients was noninferior when treated with second-line infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4; arm B) versus irinotecan (arm A). Cross-over to the other treatment on disease progression was mandated. Patients and Methods Patients who experienced treatment failure with one prior FU-based therapy and had not received prior irinotecan or oxaliplatin, either for metastatic disease or within 6 months of adjuvant FU therapy, were randomly assigned to arm A (irinotecan 350 or 300 mg/m2 every 3 weeks) or arm B (FOLFOX4). Results A total of 491 patients were randomly assigned (arm A, n = 245; arm B, n = 246); 288 (59%) had experienced treatment failure with FU for metastatic colorectal cancer. Two hundred twenty-seven patients (46%) received protocol-mandated third-line therapy (arm A, 43%; arm B, 57%). Median survival was 13.8 months (95% CI, 12.2 to 15.0 months) for initial treatment with FOLFOX4 and 14.3 months (95% CI, 12.0 to 15.9 months) for irinotecan (P = .38; hazard ratio = 0.92; 95% CI, 0.8 to 1.1). Response rates (RR; 28% v 15.5%; P = .0009) and time to progression (TTP; 6.2 v 4.4 months; P = .0009) were significantly superior with FOLFOX4. In the nonrandom subset of patients who crossed over, RR and TTP improvements with FOLFOX4 continued into third-line treatment. Irinotecan therapy was associated with more grade 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 was associated with more neutropenia and paresthesias. Conclusion In patients who experienced treatment failure with front-line FU therapy, OS does not significantly differ whether second-line therapy begins with irinotecan or FOLFOX4. FOLFOX4 produces higher RR and longer TTP. Both arms had notable OS in patients who experienced treatment failure with first-line FU therapy.
Usual Interstitial Pneumonia and Non-Specific Interstitial Pneumonia: Serial Thin-Section CT Findings Correlated with Pulmonary Function
Jeong, Yeon Joo , Lee, Kyung Soo , Müller, Néstor L. , Chung, Man Pyo , Chung, Myung Jin , Han, Joungho , Colby, Thomas V. , Kim, Seonwoo

Mayo Clinic

Korean Journal of Radiology | April 20, 2009 | Volume: 6 | Issue: 3 | Pages: 143

10.3348/kjr.2005.6.3.143 | PMID 16145289 Get It

Reduction Mammaplasty: Defining Medical Necessity
Kerrigan, Carolyn L., Collins, E. Dale, Kim, H. Myra, Schnur, Paul, Wilkins, Edwin G., Cunningham, Bruce L., Lowery, Julie C.

Mayo Clinic

Medical Decision Making | April 1, 2009 | Volume: 22 | Issue: 3 | Pages: 208-217

10.1177/0272989x0202200309 | PMID 12058778 Get It

The authors evaluated existing and new criteria for defining the medical necessity for breast reduction surgery. Two cohorts of women (those requesting breast reduction surgery [N = 266] and a group of controls [N = 184]) completed a questionnaire including breast-specific symptom severity, the Short Form 36, the EuroQol, the McGill Pain Questionnaire, and the Multidimensional Body Self Relations Questionnaire. To evaluate prediction validity, the most widely accepted decision criteria and a new definition of medical necessity were applied to the data set to determine whether women meeting the definition had more favorable outcomes than those who did not as measured by validated self-report instruments. For existing criteria, women not meeting and meeting the criterion gained equal benefit from surgery. Women meeting the new definition (2 of 7 physical symptoms all or most of the time) had significantly greater improvement scores on 4 of the 5 health burden measures compared to women not meeting this definition. The authors conclude that medical necessity for breast reduction surgery is better defined by self-report of symptoms than by existing criteria.
Acute Pancreatitis in Primary Hyperparathyroidism: A Population-Based Study
Khoo, Teck Kim, Vege, Santhi Swaroop , Abu-Lebdeh, Haitham S., Ryu, Euijung , Nadeem, Sarah , Wermers, Robert A.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 24, 2009 | Volume: 94 | Issue: 6 | Pages: 2115-2118

10.1210/jc.2008-1965 | PMID 19318456 Get It

Abstract Context: The association between acute pancreatitis and primary hyperparathyroidism (PHPT) is controversial. Objective: The aim of the study was to address the incidence and disease characteristics of acute pancreatitis in PHPT from a large inception cohort of community residents. Design and Setting: Patients with acute pancreatitis were identified in an Olmsted County, Minnesota, cohort of PHPT subjects diagnosed from 1965–2001 and compared to matched control subjects. Main Outcome Measures: The estimated rate of developing acute pancreatitis was calculated by person-years method. Cox models assessed the effect of PHPT disease status on the development of acute pancreatitis. Results: Of 684 patients with PHPT, 10 patients (1.5%) developed acute pancreatitis, compared to 32 of 1364 control patients (2.3%). The estimated rate of development of acute pancreatitis in PHPT was 114 per 100,000 person-years, compared to 140 per 100,000 person-years in control subjects (P = 0.56). The estimated hazard ratio of acute pancreatitis for PHPT relative to the control subjects was 0.84 (P = 0.89). The majority of subjects with PHPT and acute pancreatitis were women (n = 7), and the mean age was 70.6 yr at the time of acute pancreatitis. PHPT was present an average of 137 months before the development of acute pancreatitis, and contributing causes for acute pancreatitis were in identified in four patients. Maximal serum calcium levels in PHPT were not significantly associated with the development of acute pancreatitis. Conclusions: Acute pancreatitis was not increased in community patients with PHPT, and therefore, there does not appear to be a causal relationship between PHPT and acute pancreatitis.
Potential of Hydrogels Based on Poly(Ethylene Glycol) and Sebacic Acid as Orthopedic Tissue Engineering Scaffolds
Kim, Jinku , Hefferan, Theresa E., Yaszemski, Michael J. , Lu, Lichun

Mayo Clinic

Tissue Engineering Part A | March 17, 2009 | Volume: 15 | Issue: 8 | Pages: 2299-2307

10.1089/ten.tea.2008.0326 | PMID 19292677 Get It

From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells
Gaisina, Irina N. , Gallier, Franck, Ougolkov, Andrei V., Kim, Ki H. , Kurome, Toru, Guo, Songpo, Holzle, D., Luchini, Doris N., Blond, Sylvie Y., Billadeau, Daniel D. , Kozikowski, Alan P. , Ugolkov, Andrey

Mayo Clinic

Journal of Medicinal Chemistry | March 16, 2009 | Volume: 52 | Issue: 7 | Pages: 1853-1863

10.1021/jm801317h | PMID 19338355 Get It

Rapid Response Teams: A Proactive Critical Care Approach
Twedell, Diane, Moore, Kim, Twedell, Diane, Moore, Kim

Mayo Clinic

The Journal of Continuing Education in Nursing | March 11, 2009 | Volume: 39 | Issue: 11 | Pages: 488-489

10.3928/00220124-20081101-07 | PMID 19024404 Get It

Time and again, hospital code teams are dispatched to a patient in cardiac arrest only to find their resuscitative efforts unsuccessful. Are there earlier interventions that may have saved the patient? Do any warning signs exist before the patient actually goes into a full code or cardiac arrest event? The answer is a repeated yes, and the solution is a rapid response team. J Contin Educ Nurs 2008;39(11):488–489.
Controlled Release from Poly(Lactic-Co-Glycolic Acid) Microspheres Embedded in an Injectable, Biodegradable Scaffold for Bone Tissue Engineering
Kim, Chan Wook, Lu, Lichun , Currier, Bradford L. , Yaszemski, Michael J. , Kempen, Diederik H.R. , Dhert, Wouter J.A.

Mayo Clinic

Materials Science Forum | March 11, 2009 | Volume: 426-432 | Issue: No issue available | Pages: 3151-3156

10.4028/www.scientific.net/msf.426-432.3151 Get It

The Association of Tumor Microsatellite Instability Phenotype with Family History of Colorectal Cancer
Bapat, Bharati , Lindor, Noralane M. , Siegmund, Kim, Gallinger, Steve, Jass, Jeremy R., Young, Joanne , Cotterchio, Michelle , Jenkins, Mark A. , Grove, John, Casey, Graham , Thibodeau, Stephen N. , Bishop, D. Timothy , Ahnen, Dennis J. , Potter, John D. , Seminara, Daniela, Registry, and the Colon Cancer Family, Baron, John A. , Li, Lin , Zheng, Yingye , Haile, Robert W. , Hopper, John L. , Newcomb, Polly A. , Marchand, Loı̈c Le , Registry, and the Colon Cancer Family, Jenkins, Mark A , Potter, John D , Bishop, D Timothy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 9, 2009 | Volume: 18 | Issue: 3 | Pages: 967-975

10.1158/1055-9965.epi-08-0878 | PMID 19258475 Get It

Abstract Family history is a strong predictor of colorectal cancer risk; however, a diagnosis of colorectal cancer among first-degree relatives has not been systematically investigated as a function of the colorectal cancer molecular subtypes related to tumor microsatellite instability (MSI) status. We investigated whether the observable familial colorectal cancer risks differed according to tumor MSI subtypes, stratified as MSI-High (>30% instability), MSI-Low (<30% instability), and MSS (no instability). Data from 3,143 population-based colorectal cancer cases from five institutions were assessed for family history according to the Amsterdam criteria and the Bethesda guidelines, age at diagnosis, sex, tumor location, and MSI status. The distribution of patient characteristics by MSI status was compared using polytomous logistic regression. Overall, 2.8% colorectal cancer cases met the Amsterdam criteria and 37% met the Bethesda guidelines. There were 14% MSI-High, 13% MSI-Low, and 73% MSS colorectal cancers. MSI-High (P < 0.0001) and MSI-Low tumors (P = 0.01) were more proximally located than MSS tumors. MSI-High tumors were more common among females (P < 0.001). The highest proportion of MSI-High tumors occurred in cases <40 years of age whereas the age-dependent distribution of MSI-Low tumors was unchanged. MSI-High tumors showed a statistically significant association with increasing numbers of first-degree relatives with colorectal cancer (P = 0.002); this association disappeared, however, when MSI-High cases meeting Amsterdam criteria were removed from the analysis. MSI-Low tumors did not show a similar association with family history of colorectal cancer. Familial risk associated with MSI-High tumors is primarily driven by the Amsterdam-criteria patients. MSI-Low tumors may represent a distinct subtype of colorectal cancer with respect to certain epidemiologic variables studied here. (Cancer Epidemiol Biomarkers Prev 2009;18(3):967–75)